We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mayne Pharma Group Ltd | ASX:MYX | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.09 | -1.87% | 4.71 | 4.71 | 4.73 | 4.835 | 4.68 | 4.78 | 400,666 | 07:13:35 |
From Jun 2019 to Jun 2024
SYDNEY--Australian pharmaceutical group Mayne Pharma Ltd. is poised to raise around 18 million Australian dollars (US$19 million) to fund the acquisition of pain-relief product Kapanol from GlaxoSmithKline, a person familiar with the matter said Friday.
The raising, led by Credit Suisse and UBS, is being conducted at 29.5 cents a share, a 7.8% discount to the stock's last-traded price of 32 cents, the person said.
Mayne Pharma entered a trading halt early Friday pending an equity raising to fund an acquisition. A spokeswoman from Mayne Pharma did not return a call for comment. A GlaxoSmithKline spokesperson in Melbourne declined to comment on the matter.
Write to Gillian Tan at gillian.tan@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Mayne Pharma Chart |
1 Month Mayne Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
